NCT07756580
A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 6 words Show 4 more changesShow less
- Enrollment closed, study ongoing
- Final enrollment: 143 participants (planned 120)
- Primary completion date: Mar 2027 to Feb 2027
- Site details revised at 8 of 8 sites
- Notable Recruitment opened
- Trial sites expanded: 0 → 8 locations
- Minor Study sites: 1 to 0v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of Participants with Adverse Events (AEs)
Timeframe: Up to Approximately Day 141
Arms and interventions
Cohort 1 - AGN-151586 and BOTOXExperimental
Participants will receive AGN-151586 on Day 1, followed by BOTOX on Day 14.
Cohort 2 - AGN-151586 and BOTOXExperimental
Participants will receive AGN-151586 on Day 1, followed by BOTOX on Day 21.
Drugs: AGN-151586, BOTOX
Sites
8 sites in 1 country